← Back to Neuland Laboratories Ltd. overview
Neuland Laboratories Ltd. — 10-Year Financials
Annual P&L, balance sheet, and key ratios from public BSE/NSE filings.
| Period | Revenue | Net Profit | EPS (₹) | Total Assets | Shareholder Equity | ROE (%) | ROCE (%) | D/E | Net Margin (%) |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | ₹1,434 cr | ₹260 cr | ₹202.74 | ₹2,180 cr | ₹1,525 cr | 17.06% | 20.94% | 0.1x | 18.13% |
| FY2024 | ₹1,516 cr | ₹300 cr | ₹233.89 | ₹1,833 cr | ₹1,283 cr | 23.39% | 29.93% | 0.07x | 19.8% |
| FY2023 | ₹1,161 cr | ₹164 cr | ₹127.45 | ₹1,580 cr | ₹994 cr | 16.45% | 20.15% | 0.13x | 14.09% |
| FY2022 | ₹923 cr | ₹64 cr | ₹49.74 | ₹1,383 cr | ₹841 cr | 7.59% | 8.48% | 0.29x | 6.91% |
Revenue: Total income from operations (₹ crore).
EPS: Earnings per share (₹), basic.
ROE: Net profit / average shareholder equity.
ROCE: EBIT / capital employed.
D/E: Total debt / shareholder equity.
Net Margin: Net profit as a % of revenue.
All figures sourced from public BSE/NSE filings. Ratios are pre-computed estimates and may differ from primary filings due to rounding.
Educational content — not investment adviceAll financial data is sourced from public filings and shown here for educational purposes only. EquitiesIndia.com is not a SEBI-registered Investment Adviser or Research Analyst. Nothing on this page constitutes a recommendation or solicitation to transact in any security. All data is at least 90 days old. Past performance is not indicative of future results.